FeesSafety
Pluang+

Bristol Myers Squibb outgrows Novo Nordisk in 2027 with rising revenue and net income despite pricing pressures.

Market News
23 Nov 2026, 00:44 WIB
Brendan Coffey
View Source
Bullish
Bristol Myers Squibb outgrows Novo Nordisk in 2027 with rising revenue and net income despite pricing pressures.

Bristol Myers Squibb is expected to grow revenue by 3% and net income by over 40% in 2027, benefiting from new growth brands and a strong pipeline despite challenges like pricing pressures and patent expirations. Novo Nordisk, while dominant in obesity and diabetes treatments with blockbuster drugs Wegovy and Ozempic, faces revenue and net income declines in 2026 due to pricing pressures and competition, though long-term growth is anticipated as new products launch. Investors face a choice between BMY's value and growth potential versus NVO's specialized market leadership and higher margins. For 2027, Bristol Myers Squibb is recommended due to its current growth trajectory and attractive valuation.

As of Nov 23, 2026 01:01 WIB, Bristol Myers Squibb (BMY) trades at USD 58.83, closer to its 52-week high of USD 68.09, while Novo Nordisk (NVO) is at USD 37.82, near its 52-week low of USD 35.29. Despite NVO's larger market cap of $171.04B compared to BMY's $120.19B, BMY shows a positive 1-day change of +0.84%, contrasting with NVO's -2.70%. BMY's dividend yield stands at 4.29%, slightly below NVO's 4.75%, reflecting differing investor appeal as of the current trading snapshot on Pluang.

More News (BMY)

Bristol Myers Squibb offers growth and value in 2027, outperforming Novo Nordisk amid pricing pressures.

Bristol Myers Squibb offers growth and value in 2027, outperforming Novo Nordisk amid pricing pressures.

Bristol Myers Squibb (BMY) and Novo Nordisk (NVO) are healthcare leaders with different strengths: BMY in oncology and hematology, and NVO in obesity and diabetes treatments. BMY shows steady revenue and net income growth for 2027, with a low valuati...

Market News
Bullish
5 hours ago
Bristol Myers Squibb offers a 4.3% yield with strong new drug growth despite upcoming patent risks.

Bristol Myers Squibb offers a 4.3% yield with strong new drug growth despite upcoming patent risks.

Bristol Myers Squibb, a major pharmaceutical company, currently offers a 4.3% dividend yield and trades at a price-to-earnings ratio well below the industry average. Its newer drug portfolio generated nearly $7.7 billion in revenue last quarter, grow...

Market News
Bullish
1 day ago
Erasca upgraded to Buy as ERAS-0015 shows strong cancer trial results and patent issues ease.

Erasca upgraded to Buy as ERAS-0015 shows strong cancer trial results and patent issues ease.

Erasca has been upgraded from Hold to Buy following promising early trial results for its drug ERAS-0015, which showed unconfirmed response rates of 50% in pancreatic cancer and 64% in lung cancer. The company plans three registrational trials by 202...

Analyst Insights
Bullish
2 days ago
Bristol-Myers Squibb raises 2026 earnings forecast as new drug sales grow 12%

Bristol-Myers Squibb raises 2026 earnings forecast as new drug sales grow 12%

Bristol-Myers Squibb increased its full-year 2026 earnings guidance following a 12% revenue growth in its growth portfolio to $7.7 billion, driven by eight medicines each generating over $1 billion annually. The company is offsetting losses from pate...

Company Fundamentals
Bullish
3 days ago
Bristol-Myers Squibb raises 2026 earnings guidance amid strong growth in new medicines.

Bristol-Myers Squibb raises 2026 earnings guidance amid strong growth in new medicines.

Bristol-Myers Squibb reported a 12% revenue increase in its growth portfolio to $7.7 billion for Q3 2026, driven by eight medicines each generating over $1 billion annually. The company advanced four late-stage clinical trials, including FDA clearanc...

Company Fundamentals
Bullish
4 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App